CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis - PubMed (original) (raw)
. 1996 Aug 15;157(4):1333-6.
Affiliations
- PMID: 8759711
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
P J Perrin et al. J Immunol. 1996.
Abstract
The B7 family of cell surface molecules expressed on APC provides accessory signals to T cells via either CD28 or CTLA-4. However, while CD28 transduces a costimulatory signal that is required for an optimal immune response, CTLA-4 transmits a negative signal. These studies use an anti-CTLA-4 mAb to directly address the role of this T cell surface molecule in experimental allergic encephalomyelitis (EAE). CTLA-4 regulation of disease was assessed during initial immune cell interactions and during the effector stage of the encephalitogenic immune response. The effects of anti-CTLA-4 treatment were schedule dependent. CTLA-4 blockade during the onset of clinical symptoms markedly exacerbated disease, enhancing mortality. Disease exacerbation was associated with enhanced production of the encephalitogenic cytokines TNF-alpha, IFN-gamma and IL-2. Hence, CTLA-4 regulates the intensity of the autoimmune response in EAE, attenuating inflammatory cytokine production and clinical disease manifestations.
Similar articles
- Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo.
Issazadeh S, Navikas V, Schaub M, Sayegh M, Khoury S. Issazadeh S, et al. J Immunol. 1998 Aug 1;161(3):1104-12. J Immunol. 1998. PMID: 9686568 - Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Blazar BR, et al. J Immunol. 1999 Jun 1;162(11):6368-77. J Immunol. 1999. PMID: 10352249 - Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.
Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK. Perrin PJ, et al. J Immunol. 1995 Feb 1;154(3):1481-90. J Immunol. 1995. PMID: 7529805 - Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska A, Ciszak L, Boćko D, Frydecka I. Kosmaczewska A, et al. Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11266089 Review. - The B7-CD28 superfamily.
Sharpe AH, Freeman GJ. Sharpe AH, et al. Nat Rev Immunol. 2002 Feb;2(2):116-26. doi: 10.1038/nri727. Nat Rev Immunol. 2002. PMID: 11910893 Review.
Cited by
- Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.
Daei Sorkhabi A, Komijani E, Sarkesh A, Ghaderi Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L. Daei Sorkhabi A, et al. Cell Commun Signal. 2023 Nov 9;21(1):321. doi: 10.1186/s12964-023-01289-9. Cell Commun Signal. 2023. PMID: 37946301 Free PMC article. Review. - Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases.
Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Ibis B, et al. Front Immunol. 2023 Jun 5;14:1197364. doi: 10.3389/fimmu.2023.1197364. eCollection 2023. Front Immunol. 2023. PMID: 37342323 Free PMC article. Review. - CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model.
Miura Y, Isogai S, Maeda S, Kanazawa S. Miura Y, et al. Sci Rep. 2022 Sep 30;12(1):16363. doi: 10.1038/s41598-022-20694-7. Sci Rep. 2022. PMID: 36180526 Free PMC article. - The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis.
Basile MS, Bramanti P, Mazzon E. Basile MS, et al. Genes (Basel). 2022 Jul 24;13(8):1319. doi: 10.3390/genes13081319. Genes (Basel). 2022. PMID: 35893056 Free PMC article. Review. - Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.
Krovi SH, Kuchroo VK. Krovi SH, et al. Immunol Rev. 2022 May;307(1):161-190. doi: 10.1111/imr.13071. Epub 2022 Feb 10. Immunol Rev. 2022. PMID: 35142369 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical